Cytoplasmic protein tyrosine kinases play critical roles in many signal transduction events in multiple cell types making them targets for drug design. Yet their precise roles in these pathways have not yet been defined. The engagement of the T cell receptor (TCR) by its ligand, the major histocompatibility complex in association with a peptide, has been one of the most intensely studied pathways because of its importance in regulating the immune response to foreign invaders such as HIV. The activation of TCR associated kinases (Lck, Fyn, Zap-70, Csk, Itk, and others) and their subsequent phosphorylation of each other and of downstream effectors likely results in the activation of several branched and interconnected pathways ultimately resulting in IL-2 gene transcription. A central question in T cell signal transduction concerns the unique functions of Lck. This kinase appears to be activated very early in the pathway and has been studied through both organismal and somatic cell knock-outs. While these approaches and many others have demonstrated that Lck is required for TCR signal transduction its specific roles have been hard to establish because of the presence of the closely related kinase, Fyn, in the same pathway. Much of our current understanding comes from experiments which rely on making drastic changes to the normal TCR; deletion of Lck, or Fyn, attachment of irrelevant domains to different kinases, or expression of selected PTKs in non-T cell lines in """"""""add-back"""""""" experiments. The key tool which has been lacking in the study of Lck's role in T cell signal transduction is a cell-permeable highly specific inhibitor of Lck. We have recently developed a method which allows for highly specific inhibitors of individual Src-family tyrosine kinases to be developed. The key to our method is the engineering of Lck's active site to contain a new pocket that does not naturally occur in any wild-type kinase in the cell. To complement the expanded pocket, a known kinase inhibitor was modified with bulky substituents making it inactive towards wild- type kinases. The important feature of this mutation to Lck is that it is designed to be completely functionally silent, in terms of the Lck's substrate specificity and its ability to replace wild-type Lck. Engineering Lck to be structurally distinct from all other kinases in the cell, yet functionally equivalent to the wild-type Lck is the key which allows for rapid discovery of uniquely specific kinase inhibitors. This proposal seeks to generate the first specific inhibitor of Lck which can be used to study the specific role of Lck in the TCR mediated production of IL-2, PLC gamma-1 activation, and Ca2+ mobilization. By determining the precise role of Lck in these downstream events, new drug design strategies can be designed to specifically interrupt abberant T cell signal cascades resulting from autoimmune diseases, viral infections, or other disease states.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI044009-01
Application #
2727028
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Program Officer
Mccarthy, Susan A
Project Start
1998-09-01
Project End
2002-08-31
Budget Start
1998-09-01
Budget End
1999-08-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Princeton University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
002484665
City
Princeton
State
NJ
Country
United States
Zip Code
08544
Burkard, Mark E; Maciejowski, John; Rodriguez-Bravo, VerĂ³nica et al. (2009) Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol 7:e1000111
Justman, Quincey A; Serber, Zach; Ferrell Jr, James E et al. (2009) Tuning the activation threshold of a kinase network by nested feedback loops. Science 324:509-12
Niu, Hengyao; Wan, Lihong; Busygina, Valeria et al. (2009) Regulation of meiotic recombination via Mek1-mediated Rad54 phosphorylation. Mol Cell 36:393-404
Apsel, Beth; Blair, Jimmy A; Gonzalez, Beatriz et al. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 4:691-9
Bateman, Raynard L; Rauh, Daniel; Tavshanjian, Brandon et al. (2008) Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. J Biol Chem 283:35756-62
Johnson, Alexander W; Chen, Xi; Crombag, Hans S et al. (2008) The brain-derived neurotrophic factor receptor TrkB is critical for the acquisition but not expression of conditioned incentive value. Eur J Neurosci 28:997-1002
Rubenstein, Eric M; McCartney, Rhonda R; Zhang, Chao et al. (2008) Access denied: Snf1 activation loop phosphorylation is controlled by availability of the phosphorylated threonine 210 to the PP1 phosphatase. J Biol Chem 283:222-30
Park, S; Chapuis, N; Bardet, V et al. (2008) PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22:1698-706
Kurischko, Cornelia; Kuravi, Venkata K; Wannissorn, Nattha et al. (2008) The yeast LATS/Ndr kinase Cbk1 regulates growth via Golgi-dependent glycosylation and secretion. Mol Biol Cell 19:5559-78
Shirra, Margaret K; McCartney, Rhonda R; Zhang, Chao et al. (2008) A chemical genomics study identifies Snf1 as a repressor of GCN4 translation. J Biol Chem 283:35889-98

Showing the most recent 10 out of 47 publications